1. Association of Insulin-like Growth Factor 1 Concentrations with Risk for and Prognosis of Amyotrophic Lateral Sclerosis - Results from the ALS Registry Swabia
- Author
-
Dietrich Rothenbacher, Angela Rosenbohm, Wolfgang Koenig, Albert C. Ludolph, Gabriele Nagel, Raphael Simon Peter, Luc Dupuis, Institute of Epidemiology and Medical Biometry [Ulm, Allemagne], Universität Ulm - Ulm University [Ulm, Allemagne], Department of Neurology [Ulm, Allemagne], Deutsches Herzzentrum München [Munich, Allemagne] (DHM), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Munich Heart Alliance [Munich, Allemagne] (MHA), Mécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), The ALS registry Swabia and this study have been supported by the German Research Council (DFG)., and Bodescot, Myriam
- Subjects
Male ,medicine.medical_treatment ,[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology ,lcsh:Medicine ,Cohort Studies ,Prognostic markers ,Insulin-like growth factor ,0302 clinical medicine ,Germany ,Registries ,Insulin-Like Growth Factor I ,Amyotrophic lateral sclerosis ,lcsh:Science ,0303 health sciences ,Multidisciplinary ,Middle Aged ,Prognosis ,Survival Rate ,Quartile ,Female ,Cohort study ,Risk ,medicine.medical_specialty ,Article ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Survival rate ,Aged ,Proportional Hazards Models ,030304 developmental biology ,business.industry ,Proportional hazards model ,Amyotrophic Lateral Sclerosis ,lcsh:R ,Case-control study ,[SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology ,medicine.disease ,Serum samples ,Logistic Models ,Risk factors ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Case-Control Studies ,lcsh:Q ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,Biomarkers ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
We investigated the associations of serum concentration of insulin-like growth factor 1 (IGF1) with risk and prognosis of ALS in the ALS registry (October 2010–June 2014, median follow-up 67.6 months) in a case-control and cohort study, respectively. Serum samples were measured for IGF-1. Information on covariates was collected by standardized questionnaire. We applied conditional logistic regression to appraise the risk and Cox proportional hazards models to appraise the prognostic value of IGF-1. Data of 294 ALS patients (mean age 65.4 (SD 11.0) years, 60.2% men) and 504 controls were included in the case-control study. Median serum IGF-1 concentrations were slightly higher in ALS cases than in controls (101 vs. 99.5 ng/ml). IGF-1 concentrations were not associated with ALS risk in the fully adjusted model (top vs. bottom quartile: OR 1.16; 95%-CI 0.73–1.84, p for trend = 0.44). Among 293 ALS cases (mean age 65.5 (SD 10.5) years, 56.8% men) 243 died during follow-up. We found a statistically significant inverse association between continuous IGF-1 concentrations and survival (p = 0.01). Very high values IGF-1 were associated with a better prognosis of ALS suggesting that functions related to IGF-1 could be involved in survival.
- Published
- 2020